These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 9783563)

  • 61. Predictive value of obsessive-compulsive personality disorder in antiobsessional pharmacological treatment.
    Cavedini P; Erzegovesi S; Ronchi P; Bellodi L
    Eur Neuropsychopharmacol; 1997 Feb; 7(1):45-9. PubMed ID: 9088884
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? II.
    Mavissakalian M; Turner SM; Michelson L; Jacob R
    Am J Psychiatry; 1985 May; 142(5):572-6. PubMed ID: 3885761
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder.
    Pigott TA; Pato MT; L'Heureux F; Hill JL; Grover GN; Bernstein SE; Murphy DL
    J Clin Psychopharmacol; 1991 Aug; 11(4):242-8. PubMed ID: 1918422
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Absence of placebo response in obsessive-compulsive disorder.
    Mavissakalian MR; Jones B; Olson S
    J Nerv Ment Dis; 1990 Apr; 178(4):268-70. PubMed ID: 2319236
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder.
    Kronig MH; Apter J; Asnis G; Bystritsky A; Curtis G; Ferguson J; Landbloom R; Munjack D; Riesenberg R; Robinson D; Roy-Byrne P; Phillips K; Du Pont IJ
    J Clin Psychopharmacol; 1999 Apr; 19(2):172-6. PubMed ID: 10211919
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder.
    Flament MF; Rapoport JL; Murphy DL; Berg CJ; Lake CR
    Arch Gen Psychiatry; 1987 Mar; 44(3):219-25. PubMed ID: 3548637
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A Double-Blind Randomized Placebo-Controlled Pilot Study of Azithromycin in Youth with Acute-Onset Obsessive-Compulsive Disorder.
    Murphy TK; Brennan EM; Johnco C; Parker-Athill EC; Miladinovic B; Storch EA; Lewin AB
    J Child Adolesc Psychopharmacol; 2017 Sep; 27(7):640-651. PubMed ID: 28358599
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Yale-Brown Obsessive-Compulsive Scale: measures of internal consistency.
    Kim SW; Dysken MW; Pheley AM; Hoover KM
    Psychiatry Res; 1994 Feb; 51(2):203-11. PubMed ID: 8022954
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Elevated thyroid indices in children and adolescents with obsessive-compulsive disorder: effects of clomipramine treatment.
    McCracken JT; Hanna GL
    J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):581-7. PubMed ID: 16190790
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical predictors of treatment response in obsessive compulsive disorder: exploratory analyses from multicenter trials of clomipramine.
    DeVeaugh-Geiss J; Katz R; Landau P; Goodman W; Rasmussen S
    Psychopharmacol Bull; 1990; 26(1):54-9. PubMed ID: 2196627
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo.
    Goodman WK; Price LH; Rasmussen SA; Delgado PL; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1989 Jan; 46(1):36-44. PubMed ID: 2491940
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine.
    Berman I; Sapers BL; Chang HH; Losonczy MF; Schmildler J; Green AI
    J Clin Psychopharmacol; 1995 Jun; 15(3):206-10. PubMed ID: 7635998
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pulse intravenous clomipramine for depressed adolescents: double-blind, controlled trial.
    Sallee FR; Vrindavanam NS; Deas-Nesmith D; Carson SW; Sethuraman G
    Am J Psychiatry; 1997 May; 154(5):668-73. PubMed ID: 9137123
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intravenous clomipramine for a schizophrenic patient with obsessive-compulsive symptoms.
    Poyurovsky M; Weizman A
    Am J Psychiatry; 1998 Jul; 155(7):993. PubMed ID: 9659874
    [No Abstract]   [Full Text] [Related]  

  • 75. Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial.
    Vallejo J; Olivares J; Marcos T; Bulbena A; Menchón JM
    Br J Psychiatry; 1992 Nov; 161():665-70. PubMed ID: 1422616
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Lithium and tryptophan augmentation in clomipramine-resistant obsessive-compulsive disorder.
    Rasmussen SA
    Am J Psychiatry; 1984 Oct; 141(10):1283-5. PubMed ID: 6435460
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.
    Tollefson GD; Birkett M; Koran L; Genduso L
    J Clin Psychiatry; 1994 Oct; 55 Suppl():69-76; discussion 77-8. PubMed ID: 7961535
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Intravenous clomipramine and obsessive-compulsive disorder.
    Thakur AK; Remillard AJ; Meldrum LH; Gorecki DK
    Can J Psychiatry; 1991 Sep; 36(7):521-4. PubMed ID: 1933762
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder.
    Tollefson GD; Rampey AH; Potvin JH; Jenike MA; Rush AJ; kominguez RA; Koran LM; Shear MK; Goodman W; Genduso LA
    Arch Gen Psychiatry; 1994 Jul; 51(7):559-67. PubMed ID: 8031229
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Age onset subtypes of obsessive compulsive disorder: differences in clinical response to treatment with clomipramine.
    Ulloa RE; Nicolini H; Avila M; Fernández-Guasti A
    J Child Adolesc Psychopharmacol; 2007 Feb; 17(1):85-96. PubMed ID: 17343556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.